SOMNF (SomnoMed) FCF Margin % : 5.01% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is SomnoMed FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SomnoMed's Free Cash Flow for the six months ended in Dec. 2024 was $1.71 Mil. SomnoMed's Revenue for the six months ended in Dec. 2024 was $34.02 Mil. Therefore, SomnoMed's FCF Margin % for the quarter that ended in Dec. 2024 was 5.01%.

As of today, SomnoMed's current FCF Yield % is -9.00%.

The historical rank and industry rank for SomnoMed's FCF Margin % or its related term are showing as below:

SOMNF' s FCF Margin % Range Over the Past 10 Years
Min: -18.3 Med: -10.16 Max: 5.24
Current: -12.75

During the past 13 years, the highest FCF Margin % of SomnoMed was 5.24%. The lowest was -18.30%. And the median was -10.16%.

SOMNF's FCF Margin % is ranked worse than
58.24% of 831 companies
in the Medical Devices & Instruments industry
Industry Median: -4.32 vs SOMNF: -12.75

SomnoMed FCF Margin % Historical Data

The historical data trend for SomnoMed's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomnoMed FCF Margin % Chart

SomnoMed Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

Get a 7-Day Free Trial

5.24

-2.27

-9.55

-12.31

-12.74

SomnoMed Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-18.78	-6.39	-15.03	-10.51	5.01

Competitive Comparison of SomnoMed's FCF Margin %

For the Medical Devices subindustry, SomnoMed's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SomnoMed's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's FCF Margin % distribution charts can be found below:

* The bar in red indicates where SomnoMed's FCF Margin % falls into.

SomnoMed FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

SomnoMed's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-7.751	/	60.857
	=	-12.74 %

SomnoMed's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	1.705	/	34.015
	=	5.01 %

SomnoMed FCF Margin % Related Terms

Thank you for viewing the detailed overview of SomnoMed's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SomnoMed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SomnoMed Ltd (OTCPK:SOMNF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

RJV:Germany SOM:Australia

Address

20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065

Website

https://www.somnomed.com/au

SomnoMed Ltd produces and sells oral treatment of sleep-related disorder devices. It manufactures and designs premium oral appliances for the treatment of sleep-disordered breathing relieving conditions. Its products include SomnoDent, Som Tabs, Som Morning Repositioner and others. Its geographical segments include North America, Europe, and Asia-Pacific. Business operations consist of the production and sale of products treating sleep-disordered breathing, which is the only reportable segment. Substantial revenue is realized from the European region.